FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Levine Mark S.					2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [ IMVT ]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
(Last)	(First)	,	iddle)			3. Date of Earliest Transaction (Month/Day/Year) 01/26/2023							X	Officer (g below)			Other (s below)	specify		
C/O IMMUNOVANT, INC. 320 W 37TH STREET, 6TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)  NEW YORK  (City)	NY (State)	10 (Zij	018 p)			Form filed by More than									-	g Person				
		Ta	ble I - Noı	n-Deri	ı ivativ	e Se	curitie	s Acq	uired, l	Disp	osed of,	or I	Benefic	ially Ow	ned/					
1. Title of Security (Instr. 3)  2. Trans Date				th/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)				ties Acquired (A) or I Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount		(A) or (D)	Price	Transactio (Instr. 3 and				(Instr. 4)		
Common Stock <sup>(1)</sup> 01/2					26/2023				S		10,156	6	D	\$18.51	245,660			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion Date Security 3. Transaction Date Execution Date, if any (Month/Day/Year)		ate,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		te	Securities Und		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V		(A)	(D)			Expiration Date	Title		Amount or Number of Shares		(Instr. 4)				

## **Explanation of Responses:**

1. On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 35,750 of these RSUs vested on January 19, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

## Remarks:

/s/ Eva Renee Barnett, attorney-infact for Mark S. Levine 01/27/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.